Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 20/20 | 0.67 |
| ▸ | OPRL1 | P41146 | 10/20 | 0.67 |
| ▸ | OGFRL1 | Q5TC84 | 11/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4114262 | 0.81 | OPRM1 (1.00) | OPRM1OPRL1OGFRL1OPRK1OPRD1 | |
| SCHEMBL4120301 | 0.78 | OPRM1 (0.66) | OPRM1OPRL1OGFRL1OPRK1OPRD1 | |
| SCHEMBL3408893 | 0.77 | OPRM1 (0.65) | OPRM1OPRL1OGFRL1OPRK1OPRD1 | |
| SCHEMBL3407854 | 0.76 | OPRM1 (0.64) | OPRM1OPRL1OGFRL1OPRK1OPRD1 | |
| SCHEMBL3407442 | 0.74 | OPRM1 (1.00) | OPRM1OPRL1OGFRL1OPRK1OPRD1 | |
| SCHEMBL1119598 | 0.74 | OPRM1 (0.82) | OPRM1OPRL1OGFRL1OPRK1OPRD1 | |
| SCHEMBL1119831 | 0.73 | OPRM1 (0.86) | OPRM1OPRL1OGFRL1OPRK1OPRD1 | |
| SCHEMBL10038853 | 0.72 | OPRM1 (1.00) | OPRM1OPRL1OGFRL1OPRK1OPRD1 | |
| SCHEMBL517133 | 0.72 | OPRM1 (1.00) | OPRM1OPRL1OGFRL1OPRK1OPRD1 | |
| SCHEMBL681593 | 0.72 | OPRM1 (0.65) | OPRM1OPRL1OGFRL1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288430-B2 | Spiro(5.5)undecane derivatives | GRUNENTHAL GMBH (DE) | 2012-10-16 | — | — | US | claimed |
| EP-2257526-B1 | SPIRO(5.5)UNDECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-12-14 | — | — | EP | claimed |
| EP-2257526-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-08 | — | — | EP | claimed |
| WO-2009118169-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-01 | — | — | WO | claimed |
| US-20090247505-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | claimed |
| US-8288430-B2 | Spiro(5.5)undecane derivatives | GRUNENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-8288430-B2 | Spiro(5.5)undecane derivatives | GRUNENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-8288430-B2 | Spiro(5.5)undecane derivatives | GRUNENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| EP-2257526-B1 | SPIRO(5.5)UNDECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-12-14 | — | — | EP | disclosed |
| WO-2009118169-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-01 | — | — | WO | disclosed |
| US-20090247505-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247505-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247505-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247505-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | OPRL1, OPRD1, OPRM1 | OPRM1 3/4885OPRL1 1/4885OGFRL1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.